

Thrombosis and Haemostasis

International Journal
for Vascular Biology and Medicine

Editor-in-Chief:
Klaus T. Preissner, Germany

Editorial Board:
Charles Abrams, U.S.A.
Marie-Christine Alessi, France
Hellmut Augustin, Germany
Lina Badimon, Spain
Omar Benzakour, France
Francesco Bernardi, Italy
Thomas Bugge, U.S.A.
Raffaele de Caterina, Italy
Paul Declerck, Belgium
Carl-Erik Dempfle, Germany
Mieke Dewerchin, Belgium
Vincent Ellis, United Kingdom
Bernd Engelmann, Germany
David Gailani, U.S.A.
Pablo Garcia de Frutos, Spain
Samuel Goldhaber, U.S.A.
Regine Heller, Germany
Matthias Herrmann, Germany
Heiko Herwald, Sweden
Emilio Hirsch, Italy
Kurt Huber, Austria
Shaun Jackson, Australia
Nelly Kieffer, Luxemburg
Thomas Kietzmann, Germany
Steen Dalby Kristensen, Denmark
Irene Lang, Austria
Gregory Y. H. Lip, United Kingdom
Christine Mannhalter, Austria
John McVey, United Kingdom
Leonid Medved, U.S.A.
James Morrissey, U.S.A.
Laszlo Muszbek, Hungary
Frederick Ofori-Awo, Canada
Johannes Oldenburg, Germany
Karlheinz Peter, Australia
Thomas Podor, Canada
Curzio Ruegg, Switzerland
Manfred Schmitt, Germany
Wolfgang Siess, Germany
Andrzej Szczeklik, Poland
Mauro Torti, Italy
Victor W. M. van Hinsbergh, The Netherlands
Johannes Waltenberger, The Netherlands
Ulrich Walter, Germany
Steve Watson, United Kingdom
Artur-Aron Weber, Germany
Christian Weber, Germany
Jeffrey Weitz, Canada
Johann Wöhr, Austria

Index Vol. 99, 2008

Contents

Keywords

Authors

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

EDITORIAL

Thrombosis and Haemostasis: More than just a 'bloody' good journal! <i>K. T. Preissner</i>	1
---	---

EDITORIAL FOCUS

Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin <i>T. E. Warkentin</i>	2
Platelets play a direct role in sepsis-associated endothelial cell death <i>J. W. Semple</i>	249
A renaissance for the contact system in blood coagulation? <i>Y. Blat, D. Seiffert</i>	457
Perplexity of monocyte responses to C-reactive protein (CRP) <i>J. G. Filep</i>	461
A long-awaited small step forward in the management of the post-thrombotic syndrome <i>M. Levi</i>	463
Angiogenesis and the progress of vascular and tumor biology: A tribute to Judah Folkman <i>M. B. Donati, J. Gozdzikiewicz</i>	647
Expanding the role of coagulation in arterial thrombosis: Evidence from animal models using a new factor Xa inhibitor <i>F. Andreotti, E. Santucci</i>	651
Factor VIIa gets even bigger <i>W. P. Sheffield, B. J. Clarke</i>	653
Recurrent venous thromboembolism: Quite harmless after all? <i>S. V. Konstantinides</i>	655
Cell-derived microparticles: A mediator of inflammation in aortic valve stenosis? <i>Y. S. Ahn, W. Jy, L. L. Horstman, J. J. Jimenez</i>	657
Propagating factor IX-producing hepatocytes for haemophilia B therapy <i>F. A. Ofoosu</i>	799
Thromboembolic complications of sepsis: What is the incidence and pathophysiological mechanisms involved? <i>M. Holub</i>	801
Therapeutic integrin inhibition: Allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies <i>I. Ahrens, K. Peter</i>	803

OBUTARY

Judah Folkman (1933-2008) <i>H. G. Augustin, G. Breier</i>	250
---	-----

THEME ISSUE EDITORIALS

From Molecules to Medicine: New Horizons in Vascular Biology and Thrombosis <i>K. T. Preissner</i>	251
---	-----

From Molecules to Medicine: New Horizons in Vascular Biology and Thrombosis (Part II) <i>K. T. Preissner</i>	465
--	-----

Current use of biologicals in thrombosis and haemostasis <i>F. A. Oforu, T. W. Barrowcliffe</i>	805
--	-----

THEME ISSUE ARTICLES

Congenital disorders associated with platelet dysfunctions <i>P. Nurden, A. T. Nurden</i>	253
--	-----

Glycoprotein Iba and von Willebrand factor in primary platelet adhesion and thrombus formation: Lessons from mutant mice <i>W. Bergmeier, A. K. Chauhan, D. D. Wagner</i>	264
---	-----

Clearance of von Willebrand factor <i>C. V. Denis, O. D. Christophe, B. D. Oortwijn, P. J. Lenting</i>	271
---	-----

Targeting phosphoinositide 3-kinase γ to fight inflammation and more <i>L. Barberis, E. Hirsch</i>	279
--	-----

Factor VII-activating protease (FSAP): Vascular functions and role in atherosclerosis <i>S. M. Kanse, M. Parahuleva, L. Muhl, B. Kemkes-Matthes, D. Sedding, K. T. Preissner</i> ..	286
--	-----

Role of proteolysis in development of murine adipose tissue <i>V. Christiaens, I. Scroyen, H. R. Lijnen</i>	290
--	-----

Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data <i>M. Hughes, G. Y. H. Lip, on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care</i>	295
---	-----

P2 receptors, platelet function and pharmacological implications <i>C. Gachet</i>	466
--	-----

Platelet GPIb complex as a target for anti-thrombotic drug development <i>K. J. Clemetson, J. M. Clemetson</i>	473
---	-----

Platelet-vessel wall interactions in atherosclerotic disease <i>H. F. Langer, M. Gawaz</i>	480
---	-----

Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding <i>A. E. May, T. Geisler, M. Gawaz</i>	487
--	-----

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases <i>M. Wygrecka, E. Jablonska, A. Guenther, K. T. Preissner, P. Markart</i>	494
Heparin and low-molecular-weight heparin <i>E. Gray, B. Mulloy, T. W. Barrowcliffe</i>	807
The direct thrombin inhibitor hirudin <i>A. Greinacher, T. E. Warkentin</i>	819
Bivalirudin <i>T. E. Warkentin, A. Greinacher, A. Koster</i>	830
Recombinant clotting factors <i>S. W. Pipe</i>	840
Plasma-derived biological medicines used to promote haemostasis <i>F. A. Ofose, J. Freedman, J. W. Semple</i>	851
Haematopoietic growth factors and their therapeutic use <i>M. Wadhwa, R. Thorpe</i>	863
Factors that contribute to the immunogenicity of therapeutic recombinant human proteins <i>I. Mukovozov, T. Sabljic, G. Hortelano, F. A. Ofose</i>	874

REVIEW ARTICLES

Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management <i>R. Stasi, M. L. Evangelista, E. Stipa, F. Buccisano, A. Venditti, S. Amadori</i>	4
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review <i>M. Crescente, A. Di Castelnuovo, L. Iacoviello, J. Vermynen, C. Cerletti, G. de Gaetano</i>	14
Platelet functions and clinical effects in acute myelogenous leukemia <i>B. Foss, Ø. Bruserud</i>	27
Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis <i>P. Chaukiyal, A. Nautiyal, S. Radhakrishnan, S. Singh, S. D. Navaneethan</i>	38
Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings <i>R. D. Hull</i>	502

ORIGINAL ARTICLES

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Cathepsin G, a leukocyte protease, activates coagulation factor VIII <i>A. J. Gale, D. Rozenshteyn</i>	44
---	----

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting <i>R. Musso, E. Santagostino, A. Faradji, A. Iorio, J. van der Meer, J. Ingerslev, T. Lambert, M. Maas-Enriquez, E. Gorina for the KOGENATE® Bayer European PMS Study Group</i>	52
Alcohol consumption is associated with a decreased risk of venous thrombosis <i>E. R. Pomp, F. R. Rosendaal, C. J. M. Doggen</i>	59
Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: Relation to bleeding <i>S. E. M. Schols, P. E. J. van der Meijden, R. van Oerle, J. Curvers, J. W. M. Heemskerk, E. C. M. van Pampus</i>	64
Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study <i>R. Schobess, K. Kurnik, F. Friedrichs, S. Halimeh, A. Krümpel, C. Bidlingmaier, U. Nowak-Göttl</i>	71
Thrombophilias and adverse pregnancy outcome – A confounded problem! <i>W. J. Kist, N. G. Janssen, J. J. Kalk, W. M. Hague, G. A. Dekker, J. I. P. de Vries</i>	77
The antigenic binding sites of autoantibodies to factor XII in patients with recurrent pregnancy losses <i>A. Inomo, T. Sugji, Y. Fujita, H. Matsubayashi, S.-i. Izumi, M. Mikami</i>	316
Construction and functional evaluation of hirudin derivatives with low bleeding risk <i>C. Zhang, A. Yu, B. Yuan, C. Dong, H. Yu, L. Wang, C. Wu</i>	324
Calibrated automated thrombin generation in normal uncomplicated pregnancy <i>A. Rosenkranz, M. Hiden, B. Leschnik, E.-C. Weiss, D. Schlembach, U. Lang, S. Gallistl, W. Muntean</i>	331
Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis <i>J. Adomaityte, M. Farooq, R. Qayyum</i>	338
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation <i>T. R. Meier, D. D. Myers, Jr., S. K. Wroblewski, P. J. Zajkowski, A. E. Hawley, P. W. Bedard, N. E. Ballard, F. J. Londy, N. Kaila, G. P. Vlasuk, R. G. Schaub, T. W. Wakefield</i>	343
PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children <i>S. T. Kinik, N. Özbek, M. Yuce, A. C. Yazici, H. Verdi, F. B. Ataç</i>	352
The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase <i>M. A. Bukys, T. Orban, P. Y. Kim, M. E. Nesheim, M. Kalafatis</i>	511
Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect <i>I. Guella, G. Soldà, S. Spina, R. Asselta, R. Ghiotto, M. L. Tenchini, G. Castaman, S. Duga</i>	523

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases <i>F. R. Melo, P. A. S. Mourão</i>	531
Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities <i>R. J. C. Fonseca, S.-N. M. C. G. Oliveira, F. R. Melo, M. G. Pereira, N. M. B. Benevides, P. A. S. Mourão</i>	539
Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry <i>J. I. Arcelus, M. Monreal, J. A. Caprini, J. G. Guisado, M^a J. Soto, M. J. Núñez, J. C. Álvarez, and the RIETE investigators</i>	546
Prolonged in-vivo half-life of factor VIIa by fusion to albumin <i>T. Weimer, W. Wormsbächer, U. Kronthaler, W. Lang, U. Liebing, S. Schulte</i>	659
Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit <i>Z. Bagoly, F. Fazakas, I. Komáromi, G. Haramura, E. Tóth, L. Muszbek</i>	668
Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis <i>F. Dentali, M. Galli, M. Gianni, W. Ageno</i>	675
Death due to recurrent thromboembolism among younger healthier individuals hospitalized for idiopathic pulmonary embolism <i>R. H. White, H. Zhou, S. Murin</i>	683
Glycaemic control improves fibrin network characteristics in type 2 diabetes – A purified fibrinogen model <i>M. Pieters, N. Covic, F. H. van der Westhuizen, C. Nagaswami, Y. Baras, D. T. Loot, J. C. Jerling, D. Elgar, K. S. Edmondson, D. G. van Zyl, P. Rheeder, J. W. Weisel</i>	691
Successful in vivo propagation of factor IX-producing hepatocytes in mice: Potential for cell-based therapy in haemophilia B <i>K. Tatsumi, K. Ohashi, M. Kataoka, C. Tateno, M. Shibata, H. Naka, M. Shima, M. Hisanaga, H. Kanehiro, T. Okano, K. Yoshizato, Y. Nakajima, A. Yoshioka</i>	883
Venous and arterial thromboembolism in severe sepsis <i>R. L. Levine, J. R. LeClerc, J. E. Bailey, M. J. Monberg, S. Sarwat</i>	892
P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism <i>C. Ay, L. V. Jungbauer, A. Kaider, S. Koder, S. Panzer, I. Pabinger, C. Mannhalter</i>	899
Association of ADAMDEC1 haplotype with high factor VIII levels in venous thromboembolism <i>M. Berger, H. Moscatelli, B. Kulle, B. Luxembourg, K. Blouin, M. Spannagl, E. Lindhoff-Last, C. M. Schambeck</i>	905
Microparticle-associated vascular adhesion molecule-1 and tissue factor follow a circadian rhythm in healthy human subjects <i>L. A. Madden, R. V. Vince, M. E. Sandström, L. Taylor, L. McNaughton, G. Laden</i>	909

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: Influence of glycosylation, proteolysis and gene mutations <i>C. M. Millar, A. F. Riddell, S. A. Brown, R. Starke, I. Mackie, D. J. Bowen, P. V. Jenkins, J. A. van Mourik</i>	916
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis <i>M. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz, P. Wiedemann</i>	925
Platelets and Blood Cells	
Peroxisome proliferator-activated receptor γ and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles <i>D. M. Ray, S. L. Spinelli, S. J. Pollock, T. I. Murant, J. J. O'Brien, N. Blumberg, C. W. Francis, M. B. Taubman, R. P. Phipps</i>	86
Discrete functional motifs reside within the cytoplasmic tail of αV integrin subunit <i>T. A. Haas</i>	96
Simulation of platelet adhesion and aggregation regulated by fibrinogen and von Willebrand factor <i>D. Mori, K. Yano, K.-i. Tsubota, T. Ishikawa, S. Wada, T. Yamaguchi</i>	108
Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan) <i>V. L. Serebruany, A. I. Malinin, D. F. Hanley</i>	116
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment <i>D. Sibbing, S. Braun, S. Jawansky, W. Vogt, J. Mehilli, A. Schömig, A. Kastrati, N. von Beckerath</i>	121
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification <i>H. Neubauer, S. Lask, A. Engelhardt, A. Mügge</i>	357
Effect of an anti-sulfatide single-chain antibody probe on platelet function <i>P. Guchhait, C. N. Shrimpton, K. Honke, R. E. Rumbaut, J. A. Lopez, P. Thiagarajan</i>	552
C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α , on human monocytes <i>D. Hanriot, G. Bello, A. Ropars, C. Seguin-Devaux, G. Poitevin, S. Grosjean, V. Latger-Cannard, Y. Devaux, F. Zannad, V. Regnault, P. Lacolley, P.-M. Mertes, K. Hess, D. Longrois</i>	558
Allosteric regulation of $\alpha IIb\beta 3$ by $\beta 3$ 95–105 <i>T. A. Haas</i>	701
Increased levels of circulating microparticles in patients with severe aortic valve stenosis <i>P. Diehl, F. Nagy, V. Sossong, T. Helbing, F. Beyersdorf, M. Olschewski, C. Bode, M. Moser</i>	711

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO)
A. Kirkeby, L. Torup, L. Bochsén, M. Kjalke, K. Abel, K. Theilgaard-Monch, P. I. Johansson, S. E. Bjørn, J. Gerwien, M. Leist..... 720

Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy
F. Cesari, R. Marcucci, R. Caporale, R. Paniccia, E. Romano, G. F. Gensini, R. Abbate, A. M. Gori..... 930

Wound Healing and Inflammation/Infection

Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation
W. M. Lijfering, A. P. J. de Vries, N. J. G. M. Veeger, W. J. van Son, S. J. L. Bakker, J. van der Meer..... 127

Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood
H. Hochart, P. V. Jenkins, R. J. S. Preston, O. P. Smith, B. White, J. O'Donnell..... 570

Crosstalk between coagulation and inflammation during Dengue virus infection
A. Huerta-Zepeda, C. Cabello-Gutiérrez, J. Cime-Castillo, V. Monroy-Martínez, M. E. Manjarrez-Zavala, M. Gutiérrez-Rodríguez, R. Izaguirre, B. H. Ruiz-Ordaz..... 936

Endothelium and Vascular Development

Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells
Y. Nadir, B. Brenner, S. Gingis-Velitski, F. Levy-Adam, N. Ilan, E. Zcharia, E. Nadir, I. Vlodayvsky..... 133

Endothelial cell apoptosis induced by bacteria-activated platelets requires caspase-8 and -9 and generation of reactive oxygen species
C. J. Kuckleburg, R. Tiwari, C. J. Czuprynski..... 363

Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins
M. Provençal, M. Michaud, É. Beaulieu, D. Ratel1, G.-É. Rivard, D. Gingras, R. Béliveau..... 576

Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions
J.-f. Dong, M. A. Cruz, K. Aboufatova, C. Martin, H. Choi, A. L. Bergeron, S. R. Martini, M. H. Kroll, T. A. Kent..... 586

Mutation of human plasminogen kringle 1–5 enhances anti-angiogenic action via increased interaction with integrin $\alpha v \beta 3$
P.-C. Chang, Y.-J. Chang, H.-L. Wu, C.-W. Chang, C.-I. Lin, W.-C. Wang, G.-Y. Shi..... 729

Cardiovascular Biology and Cell Signalling

Factor XIa and tissue factor activity in patients with coronary artery disease
S. Butenas, A. Undas, M. T. Gissel, K. Szuldrzynski, K. Zmudka, K. G. Mann..... 142

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction <i>U. Zeymer, A. Gitt, C. Jünger, T. Bauer, T. Heer, O. Koeth, H. Wienbergen, R. Zahn, J. Senges</i>	150
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial <i>U. Zeymer, A. K. Gitt, C. Jünger, T. Bauer, O. Koeth, T. Heer, B. Mark, R. Zahn, M. Gottwik, J. Senges</i>	155
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study <i>D. J. Angiolillo, E. Bernardo, J. Palazuelos, B. Desai, I. Weisberg, F. Alfonso, L. A. Guzman, R. Hernández-Antolin, M. Z. Zenni, C. Macaya, A. Fernandez-Ortiz, T. A. Bass</i>	161
Persistent hyperfibrinogenemia in acute ischemic stroke / transient ischemic attack (TIA) <i>S. Shenhar-Tsarfaty, E. Ben Assayag, I. Bova, L. Shopin, M. Cohen, S. Berliner, I. Shapira, N. M. Bornstein</i>	169
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement <i>D. Trenk, W. Hochholzer, D. Frundi, C. Stratz, C. M. Valina, H.-P. Bestehorn, H. J. Büttner, F.-J. Neumann</i>	174
High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial <i>S. Spring, R. Simon, B. van der Loo, T. Kovacevic, C. Brockes, V. Rousson, B. Amann-Vesti, R. Koppensteiner</i>	182
Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima <i>B. Dorweiler, M. Torzewski, M. Dahm, C. J. Kirkpatrick, K. J. Lackner, C.-F. Vahl</i>	373
Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test <i>J. Orbe, M. Zudaire, R. Serrano, I. Coma-Canella, S. Martínez de Sizarrodo, J. A. Rodríguez, J. A. Páramo</i>	382
Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study <i>C. L. Carty, M. Cushman, D. Jones, L. A. Lange, L. A. Hindorff, K. Rice, N. S. Jenny, J. P. Durda, J. Walston, C. S. Carlson, D. Nickerson, R. P. Tracy, A. P. Reiner</i>	388
The C242T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and a meta-analysis <i>A. Di Castelnuovo, M. Soccio, L. Iacoviello, V. Evangelista, A. Consoli, D. Vanuzzo, S. Diviacco, M. Carluccio, L. Rignanese, R. De Caterina</i>	594
Increased thrombin generation in persons with echogenic carotid plaques <i>A.-T. W. Notø, E. Bøgeberg Mathiesen, B. Østerud, J. Amiral, A. M. Vissac, J.-B. Hansen</i>	602

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation
P. Wexberg, N. Jordanova, C. Strehlow, B. Syeda, B. Meyer, S. Charvat, G. Zorn, D. Scheinig, J. Wojta, K. Huber, D. Glogar, M. Gyöngyösi..... 739

Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease – The Indian Atherosclerosis Research Study
A. Maitra, J. Shanker, D. Dash, S. John, P. R. Sannappa, V. S. Rao, J. K. Ramanna, V. V. Kakkar..... 944

Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation
R. D. McBane, D. O. Hodge, W. E. Wysokinski..... 951

Cellular Proteolysis and Oncology

Combined use of clinical pre-test probability and D-dimer test in the diagnosis of preoperative deep venous thrombosis in colorectal cancer patients
M. T. Stender, J. B. Frøkjær, T. S. Hagedorn Nielsen, T. B. Larsen, S. Lundbye-Christensen, H. Elbrønd, O. Thorlacius-Ussing..... 396

Animal Models

Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogession and atherothrombosis in ApoE-deficient mice *in vivo*
C. Schulz, I. Konrad, S. Sauer, L. Orschiedt, M. Koellnberger, R. Lorenz, U. Walter, S. Massberg..... 190

No effect of C-reactive protein on early atherosclerosis in LDLR^{-/-} / human C-reactive protein transgenic mice
M. Torzewski, K. Reifenberg, F. Cheng, E. Wiese, I. Küpper, J. Crain, K. J. Lackner, S. Bhakdi..... 196

Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII
M. Souri, S. Koseki-Kuno, N. Takeda, M. Yamakawa, Y. Takeishi, J. L. Degen, A. Ichinose..... 401

Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tixagrelor in a rat stenosis model of venous thrombosis
S. Baxi, D. L. Crandall, T. R. Meier, S. Wroblewski, A. Hawley, D. Farris, H. Elokda, R. Sigler, R. G. Schaub, T. Wakefield, D. Myers..... 749

Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis
K. Karnicki, R. J. Leadley Jr., S. Baxi, T. Peterson, W. Wysokinski, R. D. McBane, II..... 759

Automated registration of tail bleeding in rats
P. B. Johansen, L. Henriksen, P. R. Andresen, B. Lauritzen, K. L. Jensen, T. N. Juhl, M. Tranholm..... 956

New Technologies, Diagnostic Tools and Drugs

A clinical prediction score for upper extremity deep venous thrombosis
J. Constans, L.-R. Salmi, M.-A. Sevestre-Pietri, S. Perusat, M. Nguon, M. Degeilh, J. Labarere, O. Gattolliat, C. Boulon, J.-P. Laroche, P. Le Roux, O. Pichot, I. Quéré, C. Conri, J.-L. Bosson..... 202

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia <i>B. Lobo, C. Finch, A. Howard, S. Minhas</i>	208
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry <i>J. A. Jakubowski, C. D. Payne, Y. G. Li, N. A. Farid, J. T. Brandt, D. S. Small, D. E. Salazar, K. J. Winters</i>	215
Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study <i>F. Couturaud, J. Duchemin, C. Leroyer, B. Delahousse, J. F. Abgrall, D. Mottier for the Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O)</i>	223
Further validation and simplification of the Wells clinical decision rule in pulmonary embolism <i>N. S. Gibson, M. Sohne, M. J. H. A. Kruip, L. W. Tick, V. E. Gerdes, P. M. Bossuyt, P. S. Wells, H. R. Buller on behalf of the Christopher study investigators</i>	229
The use of the VerifyNow P2Y ₁₂ point-of-care device to monitor platelet function across a range of P2Y ₁₂ inhibition levels following prasugrel and clopidogrel administration <i>J. A. Jakubowski, C. D. Payne, Y. G. Li, J. T. Brandt, D. S. Small, N. A. Farid, D. E. Salazar, K. J. Winters</i>	409
Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature <i>M. Zürcher, I. Sulzer, G. Barizzi, B. Lämmle, L. Alberio</i>	416
Monitoring high-dose heparinization during cardiopulmonary bypass – A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays <i>P. Raivio, A. Kuitunen, J. Petäjä, S. Ilveskero, R. Lassila</i>	427
Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse <i>C. Tymvios, S. Jones, C. Moore, S. C. Pitchford, C. P. Page, M. Emerson</i>	435
Selective inhibition of the platelet phosphoinositide 3-kinase p110 β as promising new strategy for platelet protection during extracorporeal circulation <i>A. Straub, H. P. Wendel, K. Dietz, D. Schiebold, K. Peter, S. M. Schoenwaelder, G. Ziemer</i>	609
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations <i>A. Tiede, R. C. Tait, D. W. Shaffer, F. Baudo, B. Boneu, C. E. Dempfle, M. H. Horellou, R. Klamroth, J. Lazarchick, A. D. Mumford, S. Schulman, C. Shiach, L. J. Bonfiglio, J. T. M. Frieling, J. Conard, M. von Depka</i>	616
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial <i>M. J. O'Donnell, S. McRae, S. R. Kahn, J. A. Julian, C. Kearon, B. MacKinnon, D. Magier, C. Strulovich, T. Lyons, S. Robinson, J. Hirsh, J. S. Ginsberg</i>	623

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

- Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma
J. Duchemin, B. Pan-Petes, B. Arnaud, M.-T. Blouch, J.-F. Abgrall 767

CASE REPORTS

- Concurrent thalidomide and radiation therapy for extensive arterio-venous malformations
A. Blinc, T. Golji, A. C. Vodnik, S. Zver..... 235

- Early postoperative obstructive prosthetic mitral valve thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation
S. De Paulis, E. Rossi, R. Zamparelli, A. Scapigliati, M. Corrado, V. De Stefano 441

- Antithrombin Cambridge II mutation as a risk factor to develop cerebral venous thrombosis
P. Barba, A. Santamaría, I. Tirado, E. Martí, J. Fontcuberta..... 443

- Multifocal thrombophlebitis and deep vein thrombosis in primary cytomegalovirus infection – A histopathological analysis
C. Jeanneret, C. Reutlinger, H. H. Hirsch, G. Cathomas, M. Rothen, F. Martius, B. C. Biedermann..... 445

- Unique heterozygous intron 22 inversion band pattern in a haemophilic male detected by long polymerase chain reaction (PCR)
B. D. M. Theophilus, M. S. Enayat, P. M. Green, J. T. Wilde, F. G. H. Hill..... 774

- Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses
M. Schindewolf, E. Lindhoff-Last 776

- Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)
E. Rota, M. Bazzan, G. Fantino 779

- Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome
D. Grimaldi, P. Bartolucci, M. Gouault-Heilmann, I. Martin-Toutain, M. Khellaf, B. Godeau 782

- Safety of bevacizumab in mild haemophilia B
C. Lambert, V. Deneys, D. Pothen, C. Hermans..... 963

LETTERS TO THE EDITOR

- Report on a disease-adapted treatment in a patient with severe factor X deficiency resulting from a homozygous factor X gene mutation
A. Gerhardt, F. Araba, R. E. Scharf, R. B. Zotz..... 238

- Comment on "Hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
J. Smout, M. Cleanthis, G. Stansby..... 239

- β 2-adrenergic receptor polymorphism and venous thromboembolism
A. R. Folsom, J. M. Peacock, E. Boerwinkle, M. Cushman..... 240

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry <i>G. Palareti, G. Agnelli, D. Imberti, M. Moia, W. Ageno, R. Pistelli, R. Rossi, M. Verso for the MASTER investigators</i>	241
The physician's estimation 'alternative diagnosis is less likely than pulmonary embolism' in the Wells rule is dependent on the presence of other required items <i>F. A. Klok, M. Zidane, R. K. Djurabi, M. Nijkeuter, M. V. Huisman</i>	244
Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER Study <i>M. Canonico, V. Olié, L. Carcaillon, P. Tubert-Bitter, P.-Y. Scarabin on behalf of the ESTrogen and THromboEmbolism Risk (ESTHER) Study Group</i>	246
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis? <i>O. Morel, N. Bernhard, D. Desprez, L. Grunebaum, J.-M. Freyssinet, F. Toti, P. Bareiss</i>	448
Comparison of the effect of different homocysteine concentrations on clot formation using human plasma and purified fibrinogen <i>R. Marchi, Z. Carvajal, J. W. Weisel</i>	451
Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry <i>N. M. Pecheniuk, D. J. Elias, X. Xu, J. H. Griffin</i>	453
von Willebrand disease, type 2B: A diagnosis more elusive than previously thought <i>E. J. Favaloro</i>	630
Type 2B-like von Willebrand disease: A creative approach to a difficult diagnosis <i>A. Casonato, F. Sartorello, E. Pontara, L. Gallinaro, M. G. Cattini</i>	632
The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis <i>T. Albert, C. Egler, S. Jakushev, U. Schuldenzucker, A. Schmitt, O. Brokemper, M. Zabe-Kühn, D. Hoffmann, J. Oldenburg, R. Schwaab</i>	634
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel <i>J. W. van Werkum, Y. Topcu, S. Postma, J. C. Kelder, C. M. Hackeng, J. M. ten Berg, F. W. A. Verheugt</i>	637
Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation <i>E. Grandone, D. Colaizzo, G. L. Tiscia, P. Vergura, E. Chinni, L. Iannaccone, I. Antinolfi, M. A. Guardascione, M. Margaglione</i>	640
Temporal trends in mortality rates from visceral vein thrombosis in paroxysmal nocturnal haemoglobinuria: An optimistic view <i>L. S. Poulou, V. Xila, G. I. Rokas, G. Karianakis, D. Bartzoudis, P. D. Ziakas</i>	642

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Identification of 5-HT ₃ receptors on human platelets: Increased surface immunoreactivity after activation with ADP and TRAP <i>C. Stratz, D. Trenk, H. S. Bhatia, C. Valina, F.-J. Neumann, B. L. Fiebich</i>	784
High factor VIIa levels do not promote tumor metastasis <i>L. W. Brüggemann, H. H. Versteeg, P. H. Reitsma, C. A. Spek</i>	787
Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels <i>G. Marchetti, B. Lunghi, G. Mazzoni, M. Cini, C. Legnani, F. Bernardi</i>	789
Thrombin regulation in neonates undergoing cardiopulmonary bypass <i>S. Långström, P. Rautiainen, L. Mildh, K. Peltola, U. Wartiovaara-Kautto, M. Heikinheimo, J. Petäjä</i>	791
Risk factors and clinical presentation of venous thromboembolism according to the age of relatives of patients with factor V Leiden <i>F. Couturaud, C. Leroyer, D. Mottier for the Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O)</i>	793
RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy <i>P. E. Westerweel, T. J. Rabelink, M. B. Rookmaaker, H.-J. Gröne, M. C. Verhaar</i>	794
Preventing venous thromboembolism in US hospitals: Are surgical patients receiving appropriate prophylaxis? <i>A. N. Amin, S. Stemkowski, J. Lin, G. Yang</i>	796
Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis <i>I. E. M. den Uijl, K. Fischer</i>	965
Request for further standardization issues for future studies in paediatric haemophilia patients – Rebuttal to “Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis” <i>S. Halimeh, A. Krümpel, R. Schobess, K. Kurnik, F. Friedrichs, C. Bidlingmaier, U. Nowak-Göttl</i>	966
Aspirin response variability assessed with the PFA-100 device <i>J.-L. Reny, I. Quéré, P. de Moerloose, P. Fontana</i>	968
Rebuttal to "Aspirin response variability assessed with the PFA-100 device" by Reny et al. <i>M. Crescente, A. Di Castelnuovo, L. Iacoviello, G. de Gaetano, C. Cerletti</i>	969
No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease <i>D. M. Smadja, M.-A. Lorient, L. A. Hindorff, L. Mellottee, P. Gaussem, J. Emmerich</i>	970
Utility of D-dimer testing in patients with clinically suspected PE and elevated C-reactive protein levels <i>F. A. Klok, R. Karamidjurabi, S. I. Velthuis, M. Nijkeuter, M. V. Huisman</i>	972
Incidence and features of heparin-induced thrombocytopenia (HIT) in burn patients: A retrospective study <i>C. Garcia Hejl, T. Leclerc, L. Bagues, T. Samson, V. Foissaud</i>	974

CONTENTS – Thrombosis and Haemostasis 2008; 99 (1-6)

Acute coronary stent thrombosis: Toward insights into possible mechanism using novel imaging methods <i>H. Zreiqat, B. James, D. Brieger, L. Kritharides, H. C. Lowe</i>	976
Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin <i>M. Paciaroni, W. Ageno, G. Agnelli</i>	978
Protective role of metallothionein in coagulatory disturbance accompanied by acute liver injury induced by LPS/D-GalN <i>K.-i. Inoue, H. Takano, M. Satoh</i>	980

KEYWORDS – Thrombosis and Haemostasis 2008; 99 (1-6)

APC resistance.....	925	calibrated automated thrombography.....	331	endothelial cell(s).....	133, 279, 729, 936
activated protein C	925	cancer.....	38, 1104	endothelial cell migration.....	576
acute myocardial infarction.....	150, 382, 487	cangrelor.....	466	endothelial dysfunction.....	995
aDAMTS-13.....	586	cardiopulmonary by-pass	427	endothelium.....	373, 586
aDAMTS-13 activity	1019	carotid stenosis	602	epidemiological studies	388
administrative data	683	case-control study.....	59	epidemiology.....	59, 683
ADP.....	466, 720	cathepsin G	44	epitope mapping	1090
adverse.....	863	catheter-related thrombosis.....	38	expression experiments.....	523
adverse events	851	cell proliferation	286	extended thrombo-prophylaxis.....	1104
aggregation.....	357	chemotherapy.....	27	extracellular signal-regulated kinases.....	576
aggrenox.....	116	child.....	1097	F1+2.....	602
air travel.....	1053	childhood obesity	352	factor IX.....	840, 851
albumin fusion	659	cholesterol-rich domains.....	1068	factor V Leiden.....	925, 1030
alcohol.....	59	chronic kidney disease	1035	factor Va.....	511
AML.....	27	circadian rhythm	909	factor VIIa.....	840
angiogenesis	576	clearance.....	916	factor VIII.....	44, 271, 840, 851, 905
angiogenesis and inhibitors	729	clinical outcome.....	14	factor VIII inhibitors	1060
animal model	190, 271, 290, 435, 749, 956	clinical practice.....	155	factor Xa.....	759
antiaggregatory agents	701	clinical prediction.....	202	factor XIa.....	142
anticoagulant factor.....	767	clinical studies/trials	150, 174, 182, 229, 487, 623, 1013	factor XII.....	316
anticoagulant polysaccharide.....	531	clopidogrel.....	121, 155, 161, 174, 215, 357, 409, 466	factor XIII.....	668
anticoagulant(s).....	502, 539, 759	coagulation.....	133, 659, 995, 1040	factor XIII Val34Leu polymorphism.....	1085
anticoagulation.....	295	coagulation factors	416, 494, 883	factor XIII-A V34L polymorphism.....	668
antiphosphatidylethanolamine antibody.....	316	coagulation inhibitors	208, 494	family cohort.....	223
antiplatelet agents/drugs.....	96, 174, 190, 466, 473, 487	coagulation markers.....	142	fasL.....	363
antiplatelet therapy.....	930	coagulation-inflammation.....	936	fibrin network.....	691
anti-sulfatide scFv and platelet function	552	collagen	720, 1068	fibrinogen.....	64, 169, 388, 944
antithrombin.....	427	colorectal cancer.....	396	fibrinogen / fibrin	96, 494, 1008
antithrombin alfa.....	616	computational simulation.....	108	fibrinogen binding.....	701
antithrombin deficiency.....	1030	confounders.....	77	fibrinogen glycation.....	691
antithrombotic.....	539	coronary artery disease.....	142, 739	fibrinolysis.....	286, 995
antithrombotic polysaccharide.....	531	coronary stenting	161	fibrinolysis inhibitors.....	290
aortic valve stenosis.....	711	coronary syndrome	382	fluid loss.....	1053
apoptosis.....	373	cost-effectiveness	295	focal adhesion complexes.....	576
Asian Indians	944	costs and cost analysis.....	1060	fondaparinux.....	208
aspirin.....	116	C-reactive protein (CRP)	196, 558, 944	fVIIa	659
aspirin resistance	14	cRM+ defects	523	fXI deficiency.....	523
aspirin variability.....	14	crostalk.....	936	gene expression	305
atherosclerosis.....	182, 190, 196, 286, 373, 388, 487, 558	cryoprecipitate.....	851	gene knock-out.....	290
atherothrombosis	190, 305, 473, 480, 487	cytokines.....	352	gene polymorphisms.....	594
atrial fibrillation.....	295, 951	cytomegalovirus	127	gene-targeting	401
Atryn.....	616	D-dimer.....	396	glycaemic control.....	691
AZD6140.....	466	deep vein (venous) thrombosis.....	208, 338, 616, 623, 749, 819, 899, 1035	glycoprotein.....	264
biological medicines.....	851	dehydration.....	1053	glycoprotein receptors	108
biosimilars	863	dengue virus.....	936	glycosylation.....	916
bivalirudin.....	830	derivative	324	GP Ib.....	473
bleeding	64, 324	diabetes (mellitus).....	14, 691, 1079	GP IIb/IIIa.....	96, 609, 1008
bleeding complications.....	1049	diagnostic accuracy	396	GP IIb/IIIa inhibitors	701
bleeding time.....	956	dilutional coagulopathy	64	growth factors.....	286
blood coagulation	286, 511	dipyridamole	116	haematopoiesis	863
blood coagulation factors.....	324	direct antithrombin agents	830	haemophilia	52
blood coagulation tests	427	direct thrombin inhibitors.....	830	haemophilia A	1090
bypassing agents	1060	drotrecogin alfa (activated).....	892	haemophilia A/B.....	883, 1060
CAD.....	944	drug-drug interaction.....	174	haemophilia therapy	883
CAD patients	930	echocardiography.....	295	<i>haemophilus somnus</i>	363
calcium	1068	elastase	668	haemostasis	401, 466, 494, 851, 995
		elderly	1079	Hageman factor.....	531
		endogenous thrombin potential.....	331	haplotypes.....	899
		endothelial activation	711	hematopoiesis	27
				heparanase	133
				heparin(s)	208, 427, 531, 570, 807
				heparins / LMWH.....	150

KEYWORDS – Thrombosis and Haemostasis 2008; 99 (1-6)

hepatology.....	675, 883	mouse.....	435	raloxifene.....	338
hereditary antithrombin deficiency.....	616	MPV.....	720	randomized trials.....	116
hirudin.....	324, 819	multiple myeloma.....	1001	rats.....	956
<i>histophilus</i>	363	mutant.....	264	reactive oxygen species (ROS).....	363, 594
hIT.....	819	mutational screening.....	523	recombinant.....	840
home monitoring.....	1097	myeloma.....	1040	recombinant factor VIII.....	52
hypercoagulability.....	1053	NADPH oxidase	594	recombinant human antithrombin.....	616
hyperglycaemia.....	691	neutrophils.....	44	recombinant human proteins.....	874
IL6	944	nitric oxide.....	182	recurrent pregnancy losses.....	316
illness severity.....	77	obesity	290, 1079	recurrent venous thrombosis.....	127
immunity.....	4	on-demand.....	71	renal failure.....	1035
immunogenicity.....	874	oral contraceptives.....	1013	renal transplant recipients.....	127
incremental cost-effectiveness.....	1060	orthopedic surgery.....	1049	reperfusion therapy.....	155
inflammation.....	44, 169, 279, 558, 570, 739	P22-phox	594	resistance.....	357
inflammation markers.....	142	P2X1.....	466	restenosis.....	286, 739
inflammatory mediators.....	570	P2Y1.....	466	reticulated platelets.....	930
inherited coagulation disorders.....	1008, 1013	P2Y12.....	215, 466	retinal vein occlusion.....	925
inherited disorders.....	253	PAI-1 gene 4G/5G polymorphism.....	352	retinoic X receptor (RXR).....	86
inherited thrombophilia.....	905	PAR-1.....	936	risk factors.....	59, 1085
inhibitor(s).....	52, 1019, 1090	PBSC.....	27	risk modeling.....	295
instrumentation.....	956	percutaneous coronary intervention.....	174	rVIIa-FP.....	659
integrins.....	96, 729, 1008	peripheral embolism.....	951	screening.....	1112
international normalized ratio.....	1097	peroxisome proliferator-activated receptor γ (PPAR γ).....	86	second-generation.....	863
ischaemic heart disease.....	1079	PFA-100.....	14	sepsis.....	892
IVIG.....	851	plaque morphology.....	602	serine protease.....	286
Japanese	116	plasminogen (-fragments).....	729	severe haemophilia A.....	71
joint damage.....	71	plasminogen activator inhibitors.....	749	shear flow.....	108
joint surgery.....	1112	platelet(s).....	27, 64, 86, 116, 161, 253, 316, 435, 586, 759, 995	signal transduction.....	279
kallikrein-kinin system	316	platelet activation inhibitors.....	701	single nucleotide polymorphisms.....	388
kininogen.....	316	platelet aggregation.....	121, 409	small-molecule inhibitor of P-selectin.....	343
kogenate.....	52	platelet function.....	14, 253	splicing mutations.....	523
laboratory	416	platelet glycoproteins.....	473, 1008	ST elevation myocardial infarction.....	155
LDLR mice.....	196	platelet immunology.....	4	statins.....	174
lenalidomide.....	1001	platelet pharmacology.....	190, 473, 609	stem cells.....	480, 863
leukaemia.....	1040	platelet physiology.....	480	stenosis.....	182, 749
leukocyte recruitment.....	373	platelet production.....	253	stent.....	739
leukocyte trafficking / recruitment.....	279	platelet reactivity.....	930	stroke.....	169, 295, 720, 892, 951
light transmission aggregometry.....	409	platelet turnover.....	930	stroke prevention.....	295
liver cirrhosis.....	1019	point-of-care (test).....	14, 1097	sulfated galactans.....	539
liver X receptors.....	558	prasugrel.....	215, 409, 466	sulfated polysaccharide.....	531
low-molecular-weight heparin.....	502, 807, 1104	preanalytic.....	416	sulfatide.....	552
low-responder.....	357	pregnancy.....	77, 331	sulfation pattern.....	539
lung.....	494	premature myocardial infarction.....	1085	surgery.....	546, 609
lymphoma.....	1040	preoperative.....	396	tail transection	956
magnesium	586	prevention.....	1035	TAT.....	602
major abdominal surgery.....	1104	primary percutaneous coronary intervention.....	155	TFPI.....	133, 576
marine red alga.....	539	primary prophylaxis.....	71	thalidomide.....	1001
matrix metalloproteinases.....	290	procoagulant factor.....	767	therapeutic proteins.....	874
mean platelet volume.....	1079	prognosis.....	155	thienopyridine.....	215, 466
menorrhagia.....	1013	prophylaxis.....	52, 1001, 1112	thrombin.....	305, 382, 819, 851
meta-analysis.....	594, 925	protease-activated receptors.....	305	thrombin generation.....	64, 223, 331, 602, 767
metabolic syndrome.....	995	proteases.....	373	thrombocytopenia.....	4, 208, 1019
metalloprotease.....	905	protein C.....	427	thromboembolism.....	295, 502, 683, 892
mice.....	264	proteolysis.....	916	thrombolysis / thrombolytic agents.....	150
microarrays.....	558	prothrombin.....	511	thrombophilia.....	77, 223, 675
microparticle tissue-factor activity.....	343	prothrombin G20210A.....	1030	thromboprophylaxis.....	38, 295, 1049
microparticles.....	86, 711, 909	p-selectin.....	343, 720, 899	thrombosis.....	44, 229, 264, 427, 435, 466, 511, 739, 759, 1001
		pulmonary embolism (PE).....	229, 338, 502, 683, 892, 899, 1030, 1035	thrombus.....	108
				ticlopidine.....	357
				tissue factor.....	142, 767, 909, 936, 1040
				TNF α	363

KEYWORDS – Thrombosis and Haemostasis 2008; 99 (1-6)

transcription factors.....	86
transglutaminase	401, 668
treatment.....	253
tumor.....	133
ultrasonography	1112
upper extremity deep vein thrombosis.....	202
vascular cell adhesion molecule-1....	909
vascular risk.....	594
VASP.....	215
veins	343
venous thromboembolism 223, 338, 396, 546, 899, 905, 1035, 1049, 1104, 1112	
venous thrombosis .. 59, 127, 202, 229, 343, 623, 675, 683, 749, 892, 1030, 1053	
verifyNow P2Y12.....	409
visceral obesity	995
von Willebrand disease..	271, 916, 1013
von Willebrand factor	264, 271, 840, 916, 1019, 1068
warfarin	1097
whole blood aggregometry	121
wound healing	401

AUTHORS – Thrombosis and Haemostasis 2008; 99 (1-6)

Abbate, R.....	930	Bidlingmaier, C.....	71, 966	Clarke, B.J.....	653
Abel, K.....	720	Biedermann, B.C.....	445	Cleanthis, M.....	239
Abgrall, J.F.....	223, 767	Bjørn, S.E.....	720	Clemetson, J.M.....	473
Aboufatova, K.....	586	Blat, Y.....	457	Clemetson, K.J.....	473
Adomaityte, J.....	338	Blinc, A.....	235	Cohen, M.....	169
Agno, W.....	241, 675, 978	Blouch, M.-T.....	767	Colaizzo, D.....	640
Agnelli, G.....	241, 978	Blouin, K.....	905	Coma-Canella, I.....	382
Ahn, Y.S.....	657	Blumberg, N.....	86	Conard, J.....	616
Ahrens, I.....	803	Bochsen, L.....	720	Conri, C.....	202
Alberio, L.....	416	Bode, C.....	711	Consoli, A.....	594
Albert, T.....	634	Boerwinkle, E.....	240	Constans, J.....	202
Alfonso, F.....	161	Bøgeberg Mathiesen, E.....	602	Corrado, M.....	441
Alvarez, J.C.....	546	Boneu, B.....	616	Couturaud, F.....	223, 793
Amadori, S.....	4	Bonfiglio, L.J.....	616	Covic, N.....	691
Amann-Vesti, B.....	182	Bornstein, N.M.....	169	Crain, J.....	196
Amin, A.N.....	796	Bosson, J.-L.....	202	Crandall, D.L.....	749
Amiral, J.....	602	Bossuyt, P.M.....	229	Crescente, M.....	14, 969
Andreotti, F.....	651	Boulon, C.....	202	Cruz, M.A.....	586
Andresen, P.R.....	956	Bova, I.....	169	Curvers, J.....	64
Angiolillo, D.J.....	161	Bowen, D.J.....	916	Cushman, M.....	240, 388
Antinolfi, I.....	640	Brandt, J.T.....	215, 409	Czuprynski, C.J.....	363
Araba, F.....	238	Braun, S.....	121		
Arcelus, J.I.....	546	Breier, G.....	250	Dahm, M.....	373
Arnaud, B.....	767	Brenner, B.....	133	Dash, D.....	944
Asselta, R.....	523	Brieger, D.....	976	De Caterina, R.....	594
Ataç, F.B.....	352	Brockes, C.....	182	de Gaetano, G.....	14, 969
Augustin, H.G.....	250	Brokemper, O.....	634	de Moerloose, P.....	968
Ay, C.....	899	Brown, S.A.....	916	De Paulis, S.....	441
		Brüggemann, L.W.....	787	De Stefano, V.....	441
Bagoly, Z.....	668	Bruserud, Ø.....	27	de Vries, A.P.J.....	127
Bailey, J.E.....	892	Buccisano, F.....	4	de Vries, J.I.P.....	77
Bakker, S.J.L.....	127	Bukys, M.A.....	511	Degeilh, M.....	202
Ballard, N.E.....	343	Buller, H.R.....	229	Degen, J.L.....	401
Baras, Y.....	691	Butenas, S.....	142	Dekker, G.A.....	77
Barba, P.....	443	Büttner, H.J.....	174	Delahousse, B.....	223
Barberis, L.....	279			Dempfle, C.E.....	616
Bareiss, P.....	448	Cabello-Gutiérrez, C.....	936	den Uijl, I.E.M.....	965
Bargues, L.....	974	Canonico, M.....	246	Deneys, V.....	963
Barizzi, G.....	416	Caporale, R.....	930	Denis, C.V.....	271
Barrowcliffe, T.W.....	805, 807	Caprini, J.A.....	546	Dentali, F.....	675
Bartolucci, P.....	782	Carcaillon, L.....	246	Desai, B.....	161
Bartzoudis, D.....	642	Carlson, C.S.....	388	Desprez, D.....	448
Bass, T.A.....	161	Carluccio, M.....	594	Devaux, Y.....	558
Baudo, F.....	616	Carty, C.L.....	388	Di Castelnuovo, A.....	14, 594, 969
Bauer, T.....	150, 155	Carvajal, Z.....	451	Diehl, P.....	711
Baxi, S.....	749, 759	Casonato, A.....	632	Dietz, K.....	609
Bazzan, M.....	779	Castaman, G.....	523	Diviacco, S.....	594
Beaulieu, É.....	576	Cathomas, G.....	445	Djurabi, R.K.....	244
Bedard, P.W.....	343	Cattini, M.G.....	632	Doggen, C.J.M.....	59
Béliveau, R.....	576	Cerletti, C.....	14, 969	Donati, M.B.....	647
Bello, G.....	558	Cesari, F.....	930	Dong, C.....	324
Ben Assayag, E.....	169	Chang, C.-W.....	729	Dong, J.-f.....	586
Benevides, N.M.B.....	539	Chang, P.-C.....	729	Dorweiler, B.....	373
Berger, M.....	905	Chang, Y.-J.....	729	Duchemin, J.....	223, 767
Bergeron, A.L.....	586	Charvat, S.....	739	Duga, S.....	523
Bergmeier, W.....	264	Chauhan, A.K.....	264	Durda, J.P.....	388
Berliner, S.....	169	Chaukiyal, P.....	38		
Bernardi, F.....	789	Cheng, F.....	196	Edmondson, K.S.....	691
Bernardo, E.....	161	Chinni, E.....	640	Egler, C.....	634
Bernhard, N.....	448	Choi, H.....	586	Elbrønd, H.....	396
Bestehorn, H.-P.....	174	Christiaens, V.....	290	Elgar, D.....	691
Beyersdorf, F.....	711	Christophe, O.D.....	271	Elias, D.J.....	453
Bhakdi, S.....	196	Cime-Castillo, J.....	936	Elokda, H.....	749
Bhatia, H.S.....	784	Cini, M.....	789	Emerson, M.....	435

AUTHORS – Thrombosis and Haemostasis 2008; 99 (1-6)

Emmerich, J.....	970	Gozdzikiewicz, J.....	647	Ilan, N.	133
Enayat, M.S.....	774	Grandone, E.....	640	Ilveskero, S.....	427
Engelhardt, A.....	357	Gray, E.....	807	Imberti, D.....	241
Evangelista, M.L.....	4	Green, P.M.....	774	Ingerslev, J.....	52
Evangelista, V.....	594	Greinacher, A.....	819, 830	Inomo, A.....	316
Fantino, G.....	779	Griffin, J.H.....	453	Inoue, K.-i.....	980
Faradji, A.....	52	Grimaldi, D.....	782	Iorio, A.....	52
Farid, N.A.....	215, 409	Gröne, H.-J.....	794	Ishikawa, T.....	108
Farooq, M.	338	Grosjean, S.....	558	Izaguirre, R.....	936
Farris, D.....	749	Grunebaum, L.....	448	Izumi, S.-i.....	316
Faude, F.....	925	Guardascione, M.A.....	640	Jablonska, E.....	494
Faude, S.....	925	Guchhait, P.....	552	Jakubowski, J.A.....	215, 409
Favaloro, E.J.....	630	Guella, I.....	523	Jakushev, S.....	634
Fazakas, F.....	668	Guenther, A.....	494	James, B.....	976
Fernandez-Ortiz, A.....	161	Guisado, J.G.....	546	Janssen, N.G.....	77
Fiebich, B.L.....	784	Gutiérrez-Rodríguez, M.....	936	Jawansky, S.....	121
Filep, J.G.....	461	Guzman, L.A.....	161	Jeanneret, C.....	445
Finch, C.....	208	Gyöngyösi, M.	739	Jenkins, P.V.....	570, 916
Fischer, K.....	965	Haas, T.A.....	96, 701	Jenny, N.S.....	388
Foissaud, V.....	974	Hackeng, C.M.....	637	Jensen, K.L.....	956
Folsom, A.R.....	240	Hagedorn Nielsen, T.S.....	396	Jerling, J.C.....	691
Fonseca, R.J.C.....	539	Hague, W.M.....	77	Jimenez, J.J.....	657
Fontana, P.	968	Halimeh, S.....	71, 966	Johansen, P.B.....	956
Fontcuberta, J.....	443	Hanley, D.F.....	116	Johansson, P.I.....	720
Foss, B.....	27	Hanriot, D.....	558	John, S.....	944
Francis, C.W.....	86	Hansen, J.-B.....	602	Jones, D.....	388
Freedman, J.....	851	Haramura, G.....	668	Jones, S.....	435
Freyssinet, J.-M.....	448	Hasenclever, D.....	925	Jordanova, N.....	739
Friedrichs, F.....	71, 966	Hawley, A.E.....	343, 749	Juhl, T.N.....	956
Frieling, J.T.M.....	616	Heemskerk, J.W.M.....	64	Julian, J.A.....	623
Frøkjær, J.B.....	396	Heer, T.....	150, 155	Jungbauer, L.V.....	899
Fruendi, D.....	174	Heikinheimo, M.....	791	Jünger, C.....	150, 155
Fujita, Y.....	316	Helbing, T.....	711	Jy, W.....	657
Gachet, C.....	466	Henriksen, L.....	956	Kahn, S.R.....	623
Gale, A.J.....	44	Hermans, C.....	963	Kaider, A.....	899
Galli, M.....	675	Hernández-Antolin, R.....	161	Kaila, N.....	343
Gallinaro, L.....	632	Hess, K.....	558	Kakkar, V.V.....	944
Gallistl, S.....	331	Hide, M.....	331	Kalafatis, M.....	511
Garcia Hejl, C.....	974	Hill, F.G.H.....	774	Kalk, J.J.....	77
Gattolliat, O.....	202	Hindorff, L.A.....	388, 970	Kanehiro, H.....	883
Gaussem, P.....	970	Hirsch, E.....	279	Kanse, S.M.....	286
Gawaz, M.....	480, 487	Hirsch, H.H.....	445	Karamidjurabi, R.....	972
Geisler, T.....	487	Hirsh, J.....	623	Karianakis, G.....	642
Gensini, G.F.....	930	Hisanaga, M.....	883	Karnicki, K.....	759
Gerdes, V.E.....	229	Hochart, H.....	570	Kastrati, A.....	121
Gerhardt, A.....	238	Hochholzer, W.....	174	Kataoka, M.....	883
Gerwien, J.....	720	Hodge, D.O.....	951	Kearon, C.....	623
Ghiotto, R.....	523	Hoffmann, D.....	634	Kelder, J.C.....	637
Gianni, M.....	675	Holub, M.....	801	Kemkes-Matthes, B.....	286
Gibson, N.S.....	229	Honke, K.....	552	Kent, T.A.....	586
Gingis-Velitski, S.....	133	Horellou, M.H.....	616	Khellaf, M.....	782
Gingras, D.....	576	Horstman, L.L.....	657	Kim, P.Y.....	511
Ginsberg, J.S.....	623	Hortelano, G.....	874	Kinik, S.T.....	352
Gissel, M.T.....	142	Howard, A.....	208	Kirkeby, A.....	720
Gitt, A.K.....	150, 155	Huber, K.....	739	Kirkpatrick, C.J.....	373
Glogar, D.....	739	Huerta-Zepeda, A.....	936	Kist, W.J.....	77
Godeau, B.....	782	Hughes, M.....	295	Kjalke, M.....	720
Golli, T.....	235	Huisman, M.V.....	244, 972	Klamroth, R.....	616
Gori, A.M.....	930	Hull, R.D.....	502	Klok, F.A.....	244, 972
Gorina, E.....	52	Iacoviello, L.....	14, 594, 969	Koder, S.....	899
Gottwik, M.....	155	Iannaccone, L.....	640	Koellnberger, M.....	190
Gouault-Heilmann, M.....	782	Ichinose, A.....	401	Koeth, O.....	150, 155

AUTHORS – Thrombosis and Haemostasis 2008; 99 (1-6)

Komáromi, I.....	668	Loriot, M.-A.....	970	Mulloy, B.....	807
Konrad, I.....	190	Lowe, H.C.....	976	Mumford, A.D.....	616
Konstantinides, S.V.....	655	Lundbye-Christensen, S.....	396	Muntean, W.....	331
Koppensteiner, R.....	182	Lunghi, B.....	789	Murant, T.I.....	86
Koseki-Kuno, S.....	401	Luxembourg, B.....	905	Murin, S.....	683
Koster, A.....	830	Lyons, T.....	623	Musso, R.....	52
Kovacevic, T.....	182	Maas-Enriquez, M.....	52	Muszbek, L.....	668
Krcova, V.....	925	Macaya, C.....	161	Myers, D.D.....	343, 749
Kriitharides, L.....	976	Mackie, I.....	916	Nadir, E.....	133
Kroll, M.H.....	586	MacKinnon, B.....	623	Nadir, Y.....	133
Kronthaler, U.....	659	Madden, L.A.....	909	Nagaswami, C.....	691
Kruip, M.J.H.A.....	229	Magier, D.....	623	Nagy, F.....	711
Krümpel, A.....	71, 966	Maitra, A.....	944	Naka, H.....	883
Kuckleburg, C.J.....	363	Malinin, A.I.....	116	Nakajima, Y.....	883
Kuitunen, A.....	427	Manjarrez-Zavala, M.E.....	936	Nautiyal, A.....	38
Kulle, B.....	905	Mann, K.G.....	142	Navaneethan, S.D.....	38
Küpper, I.....	196	Mannhalter, C.....	899	Nesheim, M.E.....	511
Kurnik, K.....	71, 966	Marchetti, G.....	789	Neubauer, H.....	357
Labarere, J.....	202	Marchi, R.....	451	Neumann, F.-J.....	174, 784
Lackner, K.J.....	196, 373	Marcucci, R.....	930	Nguon, M.....	202
Lacolley, P.....	558	Margaglione, M.....	640	Nickerson, D.....	388
Laden, G.....	909	Mark, B.....	155	Nijkeuter, M.....	244, 972
Lambert, C.....	963	Markart, P.....	494	Notø, A.-T.W.....	602
Lambert, T.....	52	Martí, E.....	443	Nowak-Göttl, U.....	71, 966
Lämmle, B.....	416	Martin, C.....	586	Núñez, M.J.....	546
Lang, U.....	331	Martinez de Sizarrondo, S.....	382	Nurden, A.T.....	253
Lang, W.....	659	Martini, S.R.....	586	Nurden, P.....	253
Lange, L.A.....	388	Martin-Toutain, I.....	782	O'Brien, J.J.....	86
Langer, H.F.....	480	Martius, F.....	445	O'Donnell, J.....	570
Långström, S.....	791	Massberg, S.....	190	O'Donnell, M.J.....	623
Laroche, J.-P.....	202	Matsubayashi, H.....	316	O'Fosu, F.A.....	799, 805, 851, 874
Larsen, T.B.....	396	May, A.E.....	487	Ohashi, K.....	883
Lask, S.....	357	Mazzoni, G.....	789	Okano, T.....	883
Lassila, R.....	427	McBane, R.D.....	759, 951	Oldenburg, J.....	634
Latger-Cannard, V.....	558	McNaughton, L.....	909	Olié, V.....	246
Lauritzen, B.....	956	McRae, S.....	623	Oliveira, S.-N.M.C.G.....	539
Lazarchick, J.....	616	Mehilli, J.....	121	Olschewski, M.....	711
Le Roux, P.....	202	Meier, T.R.....	343, 749	Oortwijn, B.D.....	271
Leadley Jr., R.J.....	759	Mellottee, L.....	970	Orban, T.....	511
LeClerc, J.R.....	892	Melo, F.R.....	531, 539	Orbe, J.....	382
Leclerc, T.....	974	Mertes, P.-M.....	558	Orschiéd, L.....	190
Legnani, C.....	789	Meyer, B.....	739	Østerud, B.....	602
Leist, M.....	720	Michaud, M.....	576	Özbek, N.....	352
Lenting, P.J.....	271	Mikami, M.....	316	Pabinger, I.....	899
Leroyer, C.....	223, 793	Mildh, L.....	791	Paciaroni, M.....	978
Leschnik, B.....	331	Millar, C.M.....	916	Page, C.P.....	435
Levi, M.....	463	Minhas, S.....	208	Palareti, G.....	241
Levine, R.L.....	892	Moia, M.....	241	Palazuelos, J.....	161
Levy-Adam, F.....	133	Monberg, M.J.....	892	Paniccia, R.....	930
Li, Y.G.....	215, 409	Monreal, M.....	546	Pan-Petes, B.....	767
Liebing, U.....	659	Monroy-Martínez, V.....	936	Panzer, S.....	899
Lijfering, W.M.....	127	Moore, C.....	435	Parahuleva, M.....	286
Lijnen, H.R.....	290	Morel, O.....	448	Páramo, J.A.....	382
Lin, C.-I.....	729	Mori, D.....	108	Payne, C.D.....	215, 409
Lin, J.....	796	Moscattelli, H.....	905	Peacock, J.M.....	240
Lindhoff-Last, E.....	776, 905	Moser, M.....	711	Pecheniuk, N.M.....	453
Lip, G.Y.H.....	295	Mottie, D.....	793	Peltola, K.....	791
Lobo, B.....	208	Mottier, D.....	223	Pereira, M.G.....	539
Londy, F.J.....	343	Mourão, P.A.S.....	531, 539	Perusat, S.....	202
Longrois, D.....	558	Mügge, A.....	357	Petäjä, J.....	427, 791
Loot, D.T.....	691	Muhl, L.....	286	Peter, K.....	609, 803
Lopez, J.A.....	552	Mukovozov, I.....	874		
Lorenz, R.....	190	Müller, M.....	925		

AUTHORS – Thrombosis and Haemostasis 2008; 99 (1-6)

Peterson, T.....	759	Sannappa, P.R.....	944	Spannagl, M.....	905
Phipps, R.P.....	86	Santagostino, E.....	52	Spek, C.A.....	787
Pichot, O.....	202	Santamaría, A.....	443	Spena, S.....	523
Pieters, M.....	691	Santucci, E.....	651	Spinelli, S.L.....	86
Pipe, S.W.....	840	Sartorello, F.....	632	Spring, S.....	182
Pistelli, R.....	241	Sarwat, S.....	892	Stansby, G.....	239
Pitchford, S.C.....	435	Satoh, M.....	980	Starke, R.....	916
Poitevin, G.....	558	Sauer, S.....	190	Stasi, R.....	4
Pollock, S.J.....	86	Scapigliati, A.....	441	Stemkowski, S.....	796
Pomp, E.R.....	59	Scarabin, P.-Y.....	246	Stender, M.T.....	396
Pontara, E.....	632	Schambeck, C.M.....	905	Stipa, E.....	4
Postma, S.....	637	Scharf, R.E.....	238	Stratz, C.....	174, 784
Pothen, D.....	963	Schaub, R.G.....	343, 749	Straub, A.....	609
Poulou, L.S.....	642	Scheinig, D.....	739	Strehlow, C.....	739
Preissner, K.T.....	1, 251, 286, 465, 494	Schiebold, D.....	609	Strulovich, C.....	623
Preston, R.J.S.....	570	Schindewolf, M.....	776	Sugi, T.....	316
Provençal, M.....	576	Schlembach, D.....	331	Sulzer, I.....	416
		Schmitt, A.....	634	Syeda, B.....	739
Qayyum, R.....	338	Schobess, R.....	71, 966	Szuldrzynski, K.....	142
Quéré, I.....	202, 968	Schoenwaelder, S.M.....	609		
		Schols, S.E.M.....	64	Tait, R.C.....	616
Rabelink, T.J.....	794	Scholz, M.....	925	Takano, H.....	980
Radhakrishnan, S.....	38	Schömig, A.....	121	Takeda, N.....	401
Raivio, P.....	427	Schuldenzucker, U.....	634	Takeishi, Y.....	401
Ramanna, J.K.....	944	Schulman, S.....	616	Tateno, C.....	883
Rao, V.S.....	944	Schulte, S.....	659	Tatsumi, K.....	883
Ratel, D.....	576	Schulz, C.....	190	Taubman, M.B.....	86
Rautiainen, P.....	791	Schwaab, R.....	634	Taylor, L.....	909
Ray, D.M.....	86	Scroyen, I.....	290	ten Berg, J.M.....	637
Regnault, V.....	558	Sedding, D.....	286	Tenchini, M.L.....	523
Rehak, J.....	925	Seguin-Devaux, C.....	558	Theilgaard-Monch, K.....	720
Rehak, M.....	925	Seiffert, D.....	457	Theophilus, B.D.M.....	774
Reifenberg, K.....	196	Semple, J.W.....	249, 851	Thiagarajan, P.....	552
Reiner, A.P.....	388	Senges, J.....	150, 155	Thorlacius-Ussing, O.....	396
Reitsma, P.H.....	787	Serebruany, V.L.....	116	Thorpe, R.....	863
Reny, J.-L.....	968	Serrano, R.....	382	Tick, L.W.....	229
Reutlinger, C.....	445	Sevestre-Pietri, M.-A.....	202	Tiede, A.....	616
Rheeder, P.....	691	Shaffer, D.W.....	616	Tirado, I.....	443
Rice, K.....	388	Shanker, J.....	944	Tiscia, G.L.....	640
Riddell, A.F.....	916	Shapira, I.....	169	Tiwari, R.....	363
Rignanese, L.....	594	Sheffield, W.P.....	653	Topcu, Y.....	637
Rivard, G.-É.....	576	Shenhar-Tsarfaty, S.....	169	Torup, L.....	720
Robinson, S.....	623	Shi, G.-Y.....	729	Torzewski, M.....	196, 373
Rodríguez, J.A.....	382	Shiach, C.....	616	Tóth, E.....	668
Rokas, G.I.....	642	Shibata, M.....	883	Toti, F.....	448
Romano, E.....	930	Shima, M.....	883	Tracy, R.P.....	388
Rookmaaker, M.B.....	794	Shopin, L.....	169	Tranholm, M.....	956
Ropars, A.....	558	Shrimpton, C.N.....	552	Trenk, D.....	174
Rosendaal, F.R.....	59	Sibbing, D.....	121	Trenk, D.....	784
Rosenkranz, A.....	331	Siegemund, A.....	925	Tsubota, K.-i.....	108
Rossi, E.....	441	Sigler, R.....	749	Tubert-Bitter, P.....	246
Rossi, R.....	241	Simon, R.....	182	Tymvios, C.....	435
Rota, E.....	779	Singh, S.....	38		
Rothen, M.....	445	Slavik, L.....	925	Undas, A.....	142
Rousson, V.....	182	Smadja, D.M.....	970		
Rozenshteyn, D.....	44	Small, D.S.....	215, 409	Vahl, C.-F.....	373
Ruiz-Ordaz, B.H.....	936	Smith, O.P.....	570	Valina, C.M.....	174, 784
Rumbaut, R.E.....	552	Smout, J.....	239	van der Loo, B.....	182
		Soccio, M.....	594	van der Meer, J.....	52, 127
Sabljić, T.....	874	Sohne, M.....	229	van der Meijden, P.E.J.....	64
Salazar, D.E.....	215, 409	Soldà, G.....	523	van der Westhuizen, F.H.....	691
Salmi, L.-R.....	202	Sossong, V.....	711	van Mourik, J.A.....	916
Samson, T.....	974	Soto, M ^a J.....	546	van Oerle, R.....	64
Sandström, M.E.....	909	Souri, M.....	401	van Pampus, E.C.M.....	64

AUTHORS – Thrombosis and Haemostasis 2008; 99 (1-6)

van Son, W.J.	127	Yoshioka, A.	883
van Werkum, J.W.	637	Yoshizato, K.	883
van Zyl, D.G.	691	Yu, A.	324
Vanuzzo, D.	594	Yu, H.	324
Veeger, N.J.G.M.	127	Yuan, B.	324
Velthuis, S.J.	972	Yuce, M.	352
Venditti, A.	4	Zabe-Kühn, M.	634
Verdi, H.	352	Zahn, R.	150
Vergura, P.	640	Zahn, R.	155
Verhaar, M.C.	794	Zajkowski, P.J.	343
Verheugt, F.W.A.	637	Zamparelli, R.	441
Vermlyen, J.	14	Zannad, F.	558
Verso, M.	241	Zcharia, E.	133
Versteeg, H.H.	787	Zenni, M.Z.	161
Vince, R.V.	909	Zeymer, U.	150, 155
Vissac, A.M.	602	Zhang, C.	324
Vlasuk, G.P.	343	Zhou, H.	683
Vlodavsky, I.	133	Ziakas, P.D.	642
Vodnik, A.C.	235	Zidane, M.	244
Vogt, W.	121	Ziemer, G.	609
von Beckerath, N.	121	Zmudka, K.	142
von Depka, M.	616	Zorn, G.	739
Wada, S.	108	Zotz, R.B.	238
Wadhwa, M.	863	Zreiqat, H.	976
Wagner, D.D.	264	Zudaire, M.	382
Wakefield, T.W.	343, 749	Zürcher, M.	416
Walston, J.	388	Zver, S.	235
Walter, U.	190		
Wang, L.	324		
Wang, W.-C.	729		
Warkentin, T.E.	2, 819, 830		
Wartiovaara-Kautto, U.	791		
Weimer, T.	659		
Weisberg, I.	161		
Weisel, J.W.	451, 691		
Weiss, E.-C.	331		
Wells, P.S.	229		
Wendel, H.P.	609		
Westerweel, P.E.	794		
Wexberg, P.	739		
White, B.	570		
White, R.H.	683		
Wiedemann, P.	925		
Wienbergen, H.	150		
Wiese, E.	196		
Wilde, J.T.	774		
Winters, K.J.	215, 409		
Wojta, J.	739		
Wormsbächer, W.	659		
Wroblewski, S.K.	343, 749		
Wu, C.	324		
Wu, H.-L.	729		
Wygrecka, M.	494		
Wysokinski, W.E.	759, 951		
Xila, V.	642		
Xu, X.	453		
Yamaguchi, T.	108		
Yamakawa, M.	401		
Yang, G.	796		
Yano, K.	108		
Yazici, A.C.	352		